Viking Therapeutics' dual-formulation obesity program could capture the most profitable patient segment starting in 2027. At 29 times forward earnings, Lilly stock assumes flawless execution with no ...

The integration aims to simplify access to Zepbound for eligible members while providing comprehensive, whole-person care to ...